Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

CNBC reports that Merck raised its full-year revenue outlook as sales of newly launched drugs accelerate. However, the pharmaceutical giant is cutting profit guidance due to charges tied to its recent acquisition of the biotech company Terns Pharmaceuticals.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton